A detailed history of Polaris Capital Management, LLC transactions in Supernus Pharmaceuticals, Inc. stock. As of the latest transaction made, Polaris Capital Management, LLC holds 42,500 shares of SUPN stock, worth $1.51 Million. This represents 0.07% of its overall portfolio holdings.

Number of Shares
42,500
Previous 42,500 -0.0%
Holding current value
$1.51 Million
Previous $1.14 Million 16.64%
% of portfolio
0.07%
Previous 0.07%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2022

Feb 09, 2023

BUY
$31.09 - $37.88 $298,464 - $363,648
9,600 Added 29.18%
42,500 $1.52 Million
Q2 2022

Aug 12, 2022

SELL
$25.33 - $34.25 $73.1 Million - $98.8 Million
-2,885,296 Reduced 98.87%
32,900 $951,000
Q2 2022

Aug 10, 2022

BUY
$25.33 - $34.25 $73.1 Million - $98.8 Million
2,885,296 Added 8769.9%
2,918,196 $45.6 Million
Q2 2021

Aug 10, 2021

BUY
$26.72 - $33.19 $879,088 - $1.09 Million
32,900 New
32,900 $1.01 Million

Others Institutions Holding SUPN

About SUPERNUS PHARMACEUTICALS, INC.


  • Ticker SUPN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 53,495,300
  • Market Cap $1.9B
  • Description
  • Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prop...
More about SUPN
Track This Portfolio

Track Polaris Capital Management, LLC Portfolio

Follow Polaris Capital Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Polaris Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Polaris Capital Management, LLC with notifications on news.